

Emily S Reisenbichler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3147436/publications.pdf>

Version: 2024-02-01

38
papers

920
citations

623734

14
h-index

477307

29
g-index

39
all docs

39
docs citations

39
times ranked

1123
citing authors

#	ARTICLE	IF	CITATIONS
1	Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. <i>JAMA Oncology</i> , 2022, 8, 607.	7.1	147
2	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunooncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
3	Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. <i>Modern Pathology</i> , 2020, 33, 1746-1752.	5.5	94
4	Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer. <i>Modern Pathology</i> , 2022, 35, 44-51.	5.5	61
5	Interobserver Concordance in Implementing the 2010 ASCO/CAP Recommendations for Reporting ER in Breast Carcinomas. <i>American Journal of Clinical Pathology</i> , 2013, 140, 487-494.	0.7	53
6	Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence. <i>Cancer Research</i> , 2017, 77, 6880-6890.	0.9	50
7	Multicomponent Lyme vaccine: Three is not a crowd. <i>Vaccine</i> , 2005, 23, 3687-3696.	3.8	46
8	Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 9.	5.2	35
9	Interobserver variability in breast carcinoma grading results in prognostic stage differences. <i>Human Pathology</i> , 2019, 94, 51-57.	2.0	25
10	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. <i>Modern Pathology</i> , 2020, 33, 354-366.	5.5	25
11	Luminal cytokeratin expression profiles of breast papillomas and papillary carcinomas and the utility of a cytokeratin 5/p63/cytokeratin 8/18 antibody cocktail in their distinction. <i>Modern Pathology</i> , 2011, 24, 185-193.	5.5	24
12	Association between low estrogen receptor positive breast cancer and staining performance. <i>Npj Breast Cancer</i> , 2020, 6, 5.	5.2	20
13	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 4839.	3.7	18
14	Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1120-1126.	2.5	17
15	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2587-2597.	7.0	16
16	Îeta-Human Chorionic Gonadotropin Production Associated with Phyllodes Tumor of the Breast: An Unusual Paraneoplastic Phenomenon. <i>Breast Journal</i> , 2009, 15, 527-530.	1.0	15
17	Characteristics and Long-Term Risk of Breast Angiosarcoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 5112-5118.	1.5	15
18	Evaluation of Dual Immunohistochemistry and Chromogenic In Situ Hybridization for HER2 on a Single Section. <i>American Journal of Clinical Pathology</i> , 2012, 137, 102-110.	0.7	14

#	ARTICLE	IF	CITATIONS
19	The clinical use of a P63/cytokeratin7/18/cytokeratin5/14 antibody cocktail in diagnostic breast pathology. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 313-318.	1.3	14
20	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IMTA study. <i>Modern Pathology</i> , 2021, 34, 2130-2140.	5.5	14
21	Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. <i>PLoS ONE</i> , 2020, 15, e0231711.	2.5	11
22	Developmental disorders and malformations of the breast. <i>Seminars in Diagnostic Pathology</i> , 2019, 36, 11-15.	1.5	10
23	LMNA&NTRK1 rearranged mesenchymal tumor (lipofibromatosis&like neural tumor) mimicking pigmented dermatofibrosarcoma protuberans. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 290-294.	1.3	9
24	MRI-Guided Breast Needle Core Biopsies: Pathologic Features of Newly Diagnosed Malignancies. <i>Breast Journal</i> , 2014, 20, 453-460.	1.0	8
25	The Predictive Ability of a CK5/p63/CK8/18 Antibody Cocktail in Stratifying Breast Papillary Lesions on Needle Biopsy. <i>American Journal of Clinical Pathology</i> , 2013, 140, 767-779.	0.7	7
26	Determination of the number of observers needed to evaluate a subjective test and its application in two PD&L1 studies. <i>Statistics in Medicine</i> , 2022, 41, 1361-1375.	1.6	6
27	Can tumor-associated macrophages in ductal carcinoma in situ on biopsy predict invasive carcinoma on excision?. <i>Human Pathology</i> , 2018, 82, 158-162.	2.0	5
28	Intraoperative sentinel lymph node evaluation: Optimizing surgical pathology practices in an era of changing clinical management. <i>Annals of Diagnostic Pathology</i> , 2018, 33, 45-50.	1.3	4
29	Reporting the greatest linear extent of ductal carcinoma in situ on needle core biopsy. <i>Human Pathology</i> , 2016, 50, 140-145.	2.0	3
30	Is tumor cellularity in primary invasive breast carcinoma of prognostic significance?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 611-617.	2.8	3
31	Lack of MDM2 interpretation guidelines contribute to diagnostic difficulty in a case of undifferentiated sarcoma. <i>Human Pathology: Case Reports</i> , 2018, 13, 1-3.	0.2	2
32	HER&neu &positive breast cancer neoadjuvant chemotherapy response after implementation of 2018 ASCO/CAP focused update. <i>Breast Journal</i> , 2021, 27, 631-637.	1.0	2
33	Non-Trophoblastic Tumors as Other Causes of Elevated Human Chorionic Gonadotrophin. <i>Laboratory Medicine</i> , 2010, 41, 183-183.	1.2	1
34	Differences in immunohistochemistry utilization by general and breast subspecialty pathologists at a large academic institution. <i>Annals of Diagnostic Pathology</i> , 2019, 42, 92-95.	1.3	1
35	Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2022, 26, 367.	2.7	1
36	Abstract P1-05-02: Intratumor molecular tumor heterogeneity in low ER-expressing primary breast tumors. <i>Cancer Research</i> , 2022, 82, P1-05-02-P1-05-02.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Current Procedural Terminology Coding in an Academic Breast Pathology Service. American Journal of Surgical Pathology, 2020, 44, 566-566.	3.7	0
38	Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions. Human Pathology, 2021, 108, 68-75.	2.0	0